Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
1,972 results
  • Thiazide diuretics are back in CKD: the case of chlorthalidone. [Review]
    Clin Kidney J. 2023 Jan; 16(1):41-51.Minutolo R, De Nicola L, … Zoccali C
  • Sodium and volume excess is the fundamental risk factor underlying hypertension in chronic kidney disease (CKD) patients, who represent the prototypical population characterized by salt-sensitive hypertension. Low salt diets and diuretics constitute the centrepiece for blood pressure control in CKD. In patients with CKD stage 4, loop diuretics are generally preferred to thiazides. Furthermore, th…
  • StatPearls: Thiazide Diuretics [BOOK]
    StatPearls. StatPearls Publishing: Treasure Island (FL)AkbariPegahPAmerican Un of Integrated SciencesKhorasani-ZadehArshiaAUpstate Medical UniversityBOOK
  • Thiazide diuretics are an FDA-approved class of drugs that inhibit the reabsorption of 3% to 5% of luminal sodium in the distal convoluted tubule of the nephron. By doing so, thiazide diuretics promote natriuresis and diuresis. Three thiazide diuretics are the most commonly used: hydrochlorothiazide (HCTZ), chlorthalidone, and indapamide. HCTZ and chlorthalidone are FDA-approved for clinical use …
  • Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. [Randomized Controlled Trial]
    N Engl J Med. 2022 12 29; 387(26):2401-2410.Ishani A, Cushman WC, … Diuretic Comparison Project Writing Group
  • CONCLUSIONS: In this large pragmatic trial of thiazide diuretics at doses commonly used in clinical practice, patients who received chlorthalidone did not have a lower occurrence of major cardiovascular outcome events or non-cancer-related deaths than patients who received hydrochlorothiazide. (Funded by the Veterans Affairs Cooperative Studies Program; number, NCT02185417.).
  • Treatment of Hypertension: A Review. [Review]
    JAMA. 2022 11 08; 328(18):1849-1861.Carey RM, Moran AE, Whelton PK
  • CONCLUSIONS: Hypertension affects approximately 116 million adults in the US and more than 1 billion adults worldwide and is a leading cause of CVD morbidity and mortality. First-line therapy for hypertension is lifestyle modification, consisting of weight loss, dietary sodium reduction and potassium supplementation, healthy dietary pattern, physical activity, and limited alcohol consumption. When drug therapy is required, first-line therapies are thiazide or thiazidelike diuretics, angiotensin-converting enzyme inhibitor or angiotensin receptor blockers, and calcium channel blockers.
  • StatPearls: Chlorthalidone [BOOK]
    StatPearls. StatPearls Publishing: Treasure Island (FL)KerndtConnor C.CCSpectrum Health/Michigan State University College of Human MedicinePatelJayeshJUniversity of Iowa Hospitals and ClinicsBOOK
  • Chlorthalidone is a medication used in the management and treatment of hypertension. It is in the thiazide-like diuretics class of drugs. This activity reviews the indications, action, and contraindications for chlorthalidone as a valuable agent in managing hypertension, edema, and calcium nephrolithiasis. This activity will highlight the mechanism of action, adverse event profile, and pharmacoki…
  • Use of Thiazides to Treat Hypertension and Advanced CKD. [Review]
    Curr Cardiol Rep. 2022 12; 24(12):2131-2137.Priamvada GS, Divyadarshini DS, Voora R
  • Hypertension is often difficult to control in patients with CKD as manifested by suboptimal control rates in this population. Use of thiazides in CKD patients has been limited as these agents are thought to be ineffective in reducing blood pressure in people with advanced CKD. This review summarizes recent studies impacting indications and safety of use of thiazide in patients with CKD and discus…
  • Comparative antiplatelet effects of chlorthalidone and hydrochlorothiazide. [Randomized Controlled Trial]
    J Clin Hypertens (Greenwich). 2022 10; 24(10):1310-1315.Bashir K, Burns T, … Hilleman DE
  • Chlorthalidone (CTD) may be superior to hydrochlorothiazide (HCTZ) in the reduction of adverse cardiovascular events in hypertensive patients. The mechanism of the potential benefit of CTD could be related to antiplatelet effects. The objective of this study was to determine if CTD or HCTZ have antiplatelet effects. This study was a prospective, double-blind, randomized, three-way crossover compa…
  • Cardio-renal interaction - Clinical trials update 2022. [Review]
    Nutr Metab Cardiovasc Dis. 2022 11; 32(11):2451-2458.Kunz M, Götzinger F, … Mahfoud F
  • CONCLUSIONS: Several important studies investigating cardio-renal interactions were recently published may affect clinical practice. The graphical abstract (Fig. 1) depicts the most relevant clinical studies investigating cardio-renal interactions.
  • Revisiting diuretic choice in chronic kidney disease. [Review]
    Curr Opin Nephrol Hypertens. 2022 09 01; 31(5):406-413.Ali S, Navaneethan SD, … Gregg LP
  • Existing guidelines offer little direction about the use of thiazide and loop diuretics in patients with chronic kidney disease (CKD). This review summarizes recent studies impacting indications and safety considerations for these agents in patients with CKD.
  • New wrinkles in hypertension management 2022. [Review]
    Curr Opin Cardiol. 2022 07 01; 37(4):317-325.Carey RM, Whelton PK
  • High blood pressure (BP) is the world's leading risk factor for cardiovascular disease (CVD) and death. This review highlights findings during the past 18 months that apply to the management of high BP in adults in the context of the 2017 American College of Cardiology/American Heart Association (AHA) BP guideline.
New Search Next